Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus

Although antidiabetic agents have been developed to target one or more of the core defects of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition of the sodium-glucose cotransporter 2 (SGLT2) induces glycosuria, reduces glucose toxicity and improves insulin sensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fioretto, Paola, Giaccari, Andrea, Sesti, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609166/
https://www.ncbi.nlm.nih.gov/pubmed/26474563
http://dx.doi.org/10.1186/s12933-015-0297-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609166/
https://www.ncbi.nlm.nih.gov/pubmed/26474563
http://dx.doi.org/10.1186/s12933-015-0297-x

Ejemplares similares